Canada markets close in 7 minutes

Caladrius Biosciences, Inc. (CLBS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8998-0.0379 (-4.04%)
As of 03:53PM EST. Market open.

Caladrius Biosciences, Inc.

110 Allen Road
2nd Floor
Basking Ridge, NJ 07920
United States
908 842 0100

Full Time Employees24

Key Executives

NameTitlePayExercisedYear Born
Dr. David J. MazzoPres, CEO & Director972.93kN/A1957
Mr. Todd C. Girolamo M.B.A., J.D., Esq.Chief Legal Officer, Sr. VP of Corp. Devel. & Corp. Sec.456.39kN/A1966
Dr. William K. Sietsema Ph.D.VP of Global Regulatory Affairs350.55kN/A1956
Mr. James NiscoVP of Fin. & TreasuryN/AN/AN/A
Mr. Gregory S. BerkinVP of Information Technology & Cyber security and Chief Information OfficerN/AN/AN/A
Mr. John D. MendittoVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Eric PowersDirector of Communications and MarketingN/AN/AN/A
Ms. Gail HollerVP of HRN/AN/A1959
Dr. Kristen K. Buck M.D.Exec. VP of R&D and Chief Medical OfficerN/AN/AN/A
Dr. Ian Zhang Ph.D., MBAPres of NeoStem (China), Inc and Managing Director of NeoStem (China), IncN/AN/A1965
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Corporate Governance

Caladrius Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.